Skip to main content
. Author manuscript; available in PMC: 2015 Aug 1.
Published in final edited form as: Cancer. 2014 Jun 4;120(15):2352–2360. doi: 10.1002/cncr.28685

Table 1.

Characteristics of AYA HOPE Participants (N=465)

All Survivors Continuous
Insurance*
(N=347)
At least some
time uninsured
(N=118)
N % % % p-value
Demographic Characteristics
Age at Diagnosis
15-19 62 13.3 80.7 19.4 0.45
20-24 81 17.4 71.6 28.4
25-39 322 69.3 74.2 25.8
Sex
Male 287 61.7 71.8 28.2 0.07
Female 178 38.3 79.2 20.8
Race
white 375 80.7 74.7 25.3 0.97
Non-white 90 19.4 74.4 25.6
Education
≤High School 130 28.0 64.6 35.4 <0.01
Some College/Vocational School 123 26.5 72.4 27.6
≥College Graduate* 212 45.6 82.1 17.9
Marital Status
Married/Living as married 198 42.6 78.3 21.7 0.12
Not married* 267 57.4 71.9 28.1
Change in Work/School after
Diagnosis
Yes* 115 24.7 80.9 19.1 0.08
No 350 75.3 72.6 27.4
Ongoing Treatment **
Yes 92 19.8 65.2 34.8 0.02
No/Don’t know* 373 80.2 76.9 23.1
Treatment Characteristics
Treatment Intensity
Least Intense 47 10.1 72.3 27.7 0.91
Moderately Intense* 290 62.4 75.2 24.8
Very Intense 128 27.5 74.2 25.8
Health Characteristics
Stage at Diagnosis
I/ II 275 59.1 72.0 28.0 0.27
III/ IV 99 21.3 79.8 20.2
Unknown/ Unstaged 91 19.6 76.9 23.1
Number of Symptoms
0-1 145 31.2 80.0 20.0 0.09
2-5* 225 48.4 74.2 25.8
6+ 95 20.4 67.4 32.6
Number of Comorbidities
0 338 72.7 74.3 25.7 0.94
1 76 16.3 75.0 25.0
2+ 51 11.0 76.5 23.5
General Health
Excellent/Very good 211 45.4 78.7 21.3 0.02
Good* 174 37.4 75.3 24.7
Fair/Poor 80 17.2 62.5 37.5
*

Category includes the following number of missing values grouped together with the most common response category for analysis: Treatment Intensity=29; Education=1; Marital Status=1; Change in Work/School after Diagnosis=29; Ongoing Treatment=9; Number of Symptoms=13; General Health=4.

**

Refers to participants currently receiving treatment who were scheduled to receive future cancer treatment at follow-up.

Measured at Baseline, except age, sex, race, ongoing treatment (see **), and comorbidities, which were measured at diagnosis.